Lactobacillus crispatus  CTV-05  (Lactin-V,  Osel) 
is  a  live  biotherapeutic  product  that  contains  a 
naturally occurring vaginal strain of L. crispatus. The placebo formulation con-
tained the same inactive ingredients as Lactin-V, 
without L. crispatus CTV-05..

Clinic follow-up visits were scheduled 4, 8, 12, 
and  24  weeks  after  enrollment. The 
data from the questionnaire are not reported here.). The  results  were  materially  unchanged  across 
the  analysis  populations. Among  the  partici-
pants  with  detectable  L.  crispatus  CTV-05,  the 
median  concentration  in  the  Lactin-V  group 
ranged from 1.7×106 to 6.2×106 CFU per millili-
ter during the treatment phase through week 12 . Overall,  adherence  to  the  assigned 
treatment  was  high.